fda maintains standards dr richard miller "drug disaster " editorial page may muddies his arguments on one hand pharmacyclics trials require "novel clinical endpoints for which there is no scientific precedent for setting the statistical threshold " on the other hand xcytrin showed "six month improvement " time to event is a well defined clinical endpoint so which is it novel endpoint or straightforward time to event i expect that the fda must keep in mind not only the current suffering patients but also future patients approving ineffective drugs would trap these future patients in a standard of care with no escape dr millers plea for "recognition that context matters" strikes me as "please lower the statistical standards for my product " if statistical standards have to become more flexible for "real advances in science and medicine" then i doubt they are real advances joseph m severs airmont n y 
